AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.

In the FIDELIO-DKD trial, finerenone lowered the risk of CKD progression and CV events in patients with CKD and type 2 diabetes compared to placebo.

The AHA has published a scientific statement on evidence for the cardiorenal protective effects of SGLT2i and GLP-1RAs on outcomes in patients with CKD and T2DM.

The biomarker NT-proBNP was as predictive as a traditional multivariable risk model for both death and CV events in T2DM patients with CVD and/or CKD.

The SGLT2 inhibitor dapagliflozin has been granted Breakthrough Therapy Designation by the FDA for patients with chronic kidney disease, with and without T2DM.

This subanalysis of the ODYSSEY OUTCOME trial evaluated whether the effects of alirocumab, compared to placebo, on MACE and all-cause death are influenced by renal function in patients with recent ACS.

This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.

ESC 2020 Ticagrelor monotherapy after 3 months DAPT reduced risk of bleeding without increasing rate of thrombotic events compared to ticagrelor plus aspirin in high risk CDK patients undergoing PCI.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.